<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01104324</url>
  </required_header>
  <id_info>
    <org_study_id>08/20E</org_study_id>
    <nct_id>NCT01104324</nct_id>
  </id_info>
  <brief_title>Osteonecrosis in Children With Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Steroid Induced Osteoporosis in the Pediatric Population Ancillary Study- Osteonecrosis in Children With Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Halton, Jacqueline, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>C17 Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Halton, Jacqueline, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute lymphoblastic leukemia is the most common form of childhood cancer with current
      treatment survival rates approaching 80%. Improved outcomes show an increased number of
      survivors at risk for long-term treatment related side effects including osteonecrosis.
      Osteonecrosis, or bone death, is caused by blood supply loss to the bone causing pain and
      poor quality of life. The hips, shoulders, knees and ankles may be affected. Pain is the
      usual presenting symptom and may become severe requiring surgical decompression or
      replacement of the affected joint. Long-term effects including arthritis and progressive
      joint difficulties will not be known for decades. This study aims to determine the risk
      factors for developing osteonecrosis that will lead to information for earlier detection and
      prevention. The study will be the basis for future intervention and prevention trials.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>osteonecrosis 1 year post leukemia therapy</measure>
    <time_frame>One year after completion of therapy for leukemia</time_frame>
    <description>Each participant will undergo MRI of hip, knee, ankle and shoulder to look for ON</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone mass density and Osteonecrosis</measure>
    <time_frame>One year post therapy for leukemia</time_frame>
    <description>Is reductions in bone mass density at diagnosis of leukemia associated with the development of ON. These patients are a subset of a lagre study where Bone mass is being measured by DEXA. We will be able to access this data to look for bone mass density</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Is Bone loss/failure to accure bone mineral and ON</measure>
    <time_frame>One year post leukemia therapy</time_frame>
    <description>Is bone loss/failure to accrue bone mineral at a normal rate during chemotherapy is/are associated with the development of ON.These patients are a subset of a lagre study where Bone mass is being measured by DEXA. We will be able to access this data to look for bone loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucocorticoid dose and ON</measure>
    <time_frame>One year post Leukemia therapy</time_frame>
    <description>Is there a glucocorticoid threshold dose, above which patients are more likely to develop ON. These patients are a subset of a lagre study where glucocorticoid dose is recorded. We will be able to access this data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methotrexate dose and ON</measure>
    <time_frame>One year post leukemia therpy</time_frame>
    <description>Is there a methotrexate threshold dose, above which patients are more likely to develop ON. These patients are a subset of a lagre study where Methotrexate dose is recorded. We will be able to access this data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obesity and ON</measure>
    <time_frame>One year post leukemia therapy</time_frame>
    <description>Is obesity either at diagnosis or during therapy associated with ON. These patients are a subset of a larger group in a larger study. They are recording height weight and BMI. We will be able to access this data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight bearing and non weight bearing activities and ON</measure>
    <time_frame>One year post leukrmia therapy</time_frame>
    <description>Does weight bearing and non-weight bearing activities play a role in the development of ON. These patients are a subset of a larger study. They are recording these activities. We will be able to use this data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperlipidemia and On</measure>
    <time_frame>One year post leukemia therapy</time_frame>
    <description>Is hyperlipidemia associated with the development of ON. Statins (cholesterol lowering medications) have been suggested as a therapeutic intervention to prevent ON. Fasting blood will be tested for lipids at at least one year post chemtherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombophilia and ON</measure>
    <time_frame>One year post leukemia therapy</time_frame>
    <description>Is thrombophilia associated with the development of ON. Blood will be tested at study entry following one year completion of chemotherapy.Blood will be drawn for protein C, protein S, antithrombin, activated protein C resistance, Factor V Leiden, prothrombin gene complex, MTHFR, lupus anticoagulant and antiphospholipid antibodies and Lipoprotein A.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Osteonecrosis</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Platlet free plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Acute lymphoblastic leukemia who have participated in the STOPP - CIS study
        will be eligible for this ancillary study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enrollment in the STOPP-CIS study

          -  Informed consent of patient or care givers

          -  &gt;5 years of age at MRI assessment

        Exclusion Criteria:

          -  Individuals with a history of claustrophobia precluding MRI assessment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacqueline Halton</last_name>
    <role>Principal Investigator</role>
    <affiliation>Childrens Hospital of Easten Ontario</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacqueline Halton</last_name>
    <phone>613 737 7600</phone>
    <phone_ext>2978</phone_ext>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lynda Hoey</last_name>
    <phone>613 737 7600</phone>
    <phone_ext>4109</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Hamilton</last_name>
      <phone>403 955 7641</phone>
    </contact>
    <investigator>
      <last_name>Victor Lewis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stollery Children's Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Linda Churcher</last_name>
      <phone>780 407 8790</phone>
    </contact>
    <investigator>
      <last_name>Bev Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BC Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Terry Viczko</last_name>
      <phone>604 875 2345</phone>
      <phone_ext>5312</phone_ext>
    </contact>
    <investigator>
      <last_name>David Dix, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winnipeg Children's Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dan Catte</last_name>
      <phone>204 977 5645</phone>
    </contact>
    <investigator>
      <last_name>Sara Israels, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alesha Warner</last_name>
      <phone>902 470-7414</phone>
    </contact>
    <investigator>
      <last_name>Beth Cummings, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Western Ontario</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martha Rolland</last_name>
    </contact>
    <investigator>
      <last_name>Beth Cairney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>, MacLennan</last_name>
      <phone>613 737 7600</phone>
    </contact>
    <investigator>
      <last_name>Jacqueline Halton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leanne Ward, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ron Grant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claude Belleville</last_name>
      <phone>(514) 345-4931</phone>
      <phone_ext>2579</phone_ext>
    </contact>
    <investigator>
      <last_name>Nathalie Alos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Children's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diane Laforte</last_name>
      <phone>(514) 412-4400</phone>
      <phone_ext>22521</phone_ext>
    </contact>
    <investigator>
      <last_name>Celia Rodd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>April 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2010</study_first_posted>
  <last_update_submitted>April 14, 2010</last_update_submitted>
  <last_update_submitted_qc>April 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jacqueline Halton MD</name_title>
    <organization>Childrens Hospital of Eastern Ontario</organization>
  </responsible_party>
  <keyword>bone health</keyword>
  <keyword>Osteonecrosis</keyword>
  <keyword>acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Osteonecrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

